Comparison of Bilateral Thoracic Paravertebral Block to Thoracic Epidural Analgesia for Post Operative Analgesia in Patients Undergoing Abdominal Surgery
NCT ID: NCT01735851
Last Updated: 2015-09-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
70 participants
INTERVENTIONAL
2012-12-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objective:
The objective of the investigators is to determine whether ultrasound (US)-guided bilateral thoracic paravertebral blocks (PVB) using curled catheter provides effective post-operative analgesia as compared to thoracic epidural analgesia in patients undergoing open abdominal bowel surgeries.
The primary outcome of this study will be the pain scores over the first 24 hours following open bowel surgeries.
Secondary outcomes include
1. Analgesic consumption in the perioperative period,
2. Block related data (block performance time, success rate, extent of sensory block, complications)
3. Hemodynamic parameter every 6 hourly
4. Incidence of side effects like nausea and pruritus scores, time to return of bowel activity
Hypothesis
Null Hypothesis: Primary.
Paravertebral blocks provide equal analgesia in the early postoperative period (first 24 hours of surgery) as compared to thoracic epidural analgesia in patients undergoing bowel surgeries by laparotomy.
Secondary
1. The analgesic consumption between PVB and TEA is not different during the first 24 hours following surgery
2. The block performance time, success rate and extent of sensory block with PVB are not different from that of TEA.
3. Side effects and complications following bilateral PVB are not different from those occurring after TEA
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Continuous Paravertebral Block by Intraoperative Direct Access Versus Systemic Analgesia for Postthoracotomy Pain Relief
NCT04482192
Comparison of Thoracic Epidural Analgesia and Intercostal Blockade in Patients Undergoing Thoracotomy
NCT03721250
Thoracic Epidural Analgesia and Bilateral Erector Spinae Plane Block on Postoperative Pain in Open Heart Surgeries
NCT06098859
The Comparison of the Analgesic Efficacy and Hemodynamic Effects of Paravertebral Block Compared With Paravertebral and Intercostal Nerve Block for Thoracotomy in Adults.
NCT04715880
Ultrasound Guided Retrolaminar Versus Erector Spinae Plane Block for Postoperative Analgesia
NCT04531215
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All blocks will be performed in the block room using standard monitoring, sterile precautions and titrated intravenous sedation with fentanyl and midazolam. During block performance one anesthetist and one assistant will be present. Due to the necessity of handling the equipment these staff will not be blinded. All patients will receive supplemental oxygen.
Group 1: Group 1 will receive a catheter congruent TEA. The catheters will be inserted using ultrasound to assess level as well as the best space to insert the epidural catheter between T7 and T9. The epidural space will be identified using the loss of resistance technique. After a test dose to rule out intravascular and intrathecal placement of the catheter using 3mL of 2% lidocaine with 5mcg/mL of epinephrine, the initial block will be made with 0.25% bupivacaine 5 mL followed by 3 mL aliquots administered every 5 minutes to establish a block between T8 and T12. An infusion will be started at 8 mL/hour with 0.1 % bupivacaine with 10 microgram/mL of dilaudid and continued for 72 hours. Additional nurse administered boluses of 5-10mL of the standard solution will be allowed via the epidural catheter every 6hourly if needed for pain control followed by an increase in the basal infusion rate up to a maximum of 14mL/hr. Patients will be allowed to self-administer additional boluses of 3mL of the standard infusate every 20minutes (PCEA) as per the standard practice at this hospital. Time to initiate the block and the failures will be documented. If the block fails, patients will receive intravenous PCA with dilaudid and the patient will be dropped out of the study for efficacy data.
Group 2 will have bilateral PVB catheters inserted using the ultrasound. Patients will be in prone position and will receive intravenous sedation similar to Group 1. The T8 spine will be identified and marked counting from the lumbar area. A high-frequency linear ultrasound probe will be positioned in the T8/9 intercostal space with the transverse process and pleura in the field as well as the internal intercostal membrane. (about 2.5 cm lateral to the spinous process) Using ultrasound guidance and an in-plane approach, a 17 gauge Tuohy needle connected to 15 mL of 0.5% ropivacaine via an extension tubing will be inserted to puncture the internal intercostal membrane. Injection of local anesthetic will push the pleura away, which will be the end point of needle position (the current standard technique in the the investigators institution). A curved pigtail catheter will be inserted while observing its delivery extrapleurally and further 5mL of local anesthetic will be injected while observing further movement of pleura. A similar procedure will be done on the contralateral side at the same level. The catheter will be secured to the skin and covered with dermabond and tegaderm. Following this, 0.2% ropivacaine will be infused at a rate of 7 mlLhr via each catheter for the next 72 hours post-operatively. They will also receive intravenous patient controlled analgesia with dilaudid at a dose of 0.2mg with a lock out of 6 mins. Additional nurse administered boluses of 5-10mL of ropivacaine 0.2% via the paravetebral catheters will be permitted every 6 hourly to the side of maximal pain. The position of the catheter will be confirmed on the routine post-operative chest x ray following the injection of contrast (Isovue: 2 mL). The sensory block extent will be documented at 15 minutes after the initial injection and prior to moving the patient to the OR. Time to initiate the block and the failure rate will be documented.
US image of paravertebral space before and after LA injection (IIM: internal intercostal membrane; TP: transverse process; LA: local anesthetic)
As soon as the arterial line is inserted in the operating room for monitoring purposes, 10mL of blood will be collected for measuring plasma ropivacaine levels. This measurement will be repeated on arrival in the PACU along with routine postoperative arterial blood gas analysis. Plasma ropivacaine level will be measured on postoperative day 1 at 6AM with the blood drawn along with routine postoperative blood work (venous sample)
Cases with a failure to establish a block 30 minutes after local anesthetic injection will be considered as block failure and the patient will be excluded from the efficacy part of the study. These patients will receive intravenous patient controlled analgesia. Once the effectiveness and level of the block is confirmed the patient will be moved to the operating room for the surgery under standardized general anesthesia using fentanyl 2-3µg/Kg, propofol 2 mg/kg and rocuronium 0.8-1.0 mg/kg for intubation followed by maintenance with desflurane in air-oxygen mixture. Vasopressors (Ephedrine and phenylephrine) will be administered as needed to control hemodynamics and the total dose used will be recorded.
The patients will be assessed for pain during rest and coughing/activity immediately after the surgery, every 15 minutes for first 2 hrs and 6 hourly thereafter until 24 hours after the removal of epidural or block catheters. Patients whose VRS scores are higher than 5/10 in PACU, apart from getting a bolus in the epidural or PVB may also receive IV Hydromorphone 0.2 mg every 5 minutes till pain subsides to a score of 3/10. Nausea will be documented using a categorical scale (none, mild, moderate and severe), pruritus scores will be recorded every 12 hours (categorical scale, none, mild, moderate and severe). Time to onset of bowel sounds, time to first flatus and time to first bowel movement would also be recorded with time 0 being the arrival time in PACU. Post-operative hemodynamic changes, blood pressure and urine output will be documented every 6 hours. Duration of significant hypotension will be computed from the nursing chart, significant hypotension being systolic BP less than 90 mm Hg. Patient satisfaction will be documented on a visual analogue scale where 0 is totally dissatisfied and 100 is totally satisfied. Adverse events such as local anesthetic toxicity, wound infection, dehiscence, urinary retention, cognitive dysfunction and neurological deficits will be prospectively collected. The failure rate of both the techniques and the number of attempts will also be recorded.
This is an open label study to document the effectiveness of bilateral PVB in bowel surgeries. The investigators plan to do a double blind study following the present study if the results are encouraging. The second concern is that 2 different local anesthetics are used for the 2 limbs but at equianalgesic concentrations for the infusion.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Thoracic epidural analgesia
Group 1 will receive a catheter congruent TEA. The epidural space will be identified using the loss of resistance technique. After a test dose to rule out intravascular and intrathecal placement of the catheterthe initial block will be made with 0.25% bupivacaine 5 mL followed by 3 mL aliquots administered every 5 minutes to establish a block between T8 and T12. An infusion will be started at 8 mL/hour with 0.1 % bupivacaine with 10microgram/mL of dilaudid and continued for 72 hours. Additional nurse administered boluses of 5-10mL of the standard solution will be allowed via the epidural catheter every 6hourly for poor pain control followed by an increase in the basal infusion rate up to a maximum of 14mL/hr. Patients will be allowed to self administer additional boluses of 3mL of the standard infusate every 20minutes (PCEA)
Thoracic epidural analgesia
Bilateral Paravertebral block
Group 2 will have bilateral PVB catheters inserted using the ultrasound with patients prone. A high-frequency linear probe will used to visualize the transverse process, pleura and the internal intercostal membrane. A 17 guage Tuohy needle will be inserted to puncture the internal intercostal membrane. Injection of local anesthetic will push the pleura away, which will be the end point of needle position. A curved pigtail catheter will be inserted and further 5mL of local anesthetic will be injected while observing further movement of pleura. A similar procedure will be done on the contralateral side at the same level. Infusion of 0.2% ropivacaine will be continued for the next 72 hours. They will also receive IVPCA and additional nurse administered boluses of 5-10mL of ropivacaine 0.2% in the PVB every 6 hourly to the side of maximal pain.
Bilateral Paravertebral block
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thoracic epidural analgesia
Bilateral Paravertebral block
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. ASA Class I, II, III -
Exclusion Criteria
2. Patients with coexisting hematological disorder or with deranged coagulation parameters.
3. Patients with pre-existing major organ dysfunction such as hepatic and renal failure.
4. Patients with anatomical deformity of spine
5. Psychiatric illnesses
6. Emergency surgery
7. Lack of informed consent.
8. Allergy to any of the drugs used in the study
9. Contraindications to epidural analgesia -
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sugantha Ganapathy
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
London Health Sciences Centre University Hospital
London, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Finucane BT, Ganapathy S, Carli F, Pridham JN, Ong BY, Shukla RC, Kristoffersson AH, Huizar KM, Nevin K, Ahlen KG; Canadian Ropivacaine Research Group. Prolonged epidural infusions of ropivacaine (2 mg/mL) after colonic surgery: the impact of adding fentanyl. Anesth Analg. 2001 May;92(5):1276-85. doi: 10.1097/00000539-200105000-00038.
Luyet C, Meyer C, Herrmann G, Hatch GM, Ross S, Eichenberger U. Placement of coiled catheters into the paravertebral space. Anaesthesia. 2012 Mar;67(3):250-5. doi: 10.1111/j.1365-2044.2011.06988.x.
Sondekoppam RV, Uppal V, Brookes J, Ganapathy S. Bilateral Thoracic Paravertebral Blocks Compared to Thoracic Epidural Analgesia After Midline Laparotomy: A Pragmatic Noninferiority Clinical Trial. Anesth Analg. 2019 Sep;129(3):855-863. doi: 10.1213/ANE.0000000000004219.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HSREB UWO 103035
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.